Altimmune, Inc. (NASDAQ:ALT) Given Average Rating of "Buy" by Brokerages

Altimmune, Inc. (NASDAQ:ALT - Get Free Report) has received a consensus rating of "Buy" from the six research firms that are currently covering the company, MarketBeat Ratings reports. One investment analyst has rated the stock with a hold rating, four have issued a buy rating and one has issued a strong buy rating on the company. The average 1 year price target among analysts that have updated their coverage on the stock in the last year is $19.00.

Several research firms recently weighed in on ALT. Wall Street Zen cut Altimmune from a "hold" rating to a "sell" rating in a research note on Saturday, June 14th. HC Wainwright reissued a "buy" rating and set a $12.00 price objective on shares of Altimmune in a report on Friday, June 27th. Finally, William Blair restated a "market perform" rating on shares of Altimmune in a research report on Friday, June 27th.

Altimmune Price Performance

Shares of Altimmune stock traded down $0.14 during trading on Tuesday, hitting $4.76. 6,331,621 shares of the stock were exchanged, compared to its average volume of 3,331,254. The firm's 50-day moving average price is $5.71 and its 200 day moving average price is $5.99. The stock has a market cap of $386.08 million, a price-to-earnings ratio of -3.78 and a beta of 0.47. Altimmune has a 12-month low of $2.90 and a 12-month high of $11.16.

Altimmune (NASDAQ:ALT - Get Free Report) last posted its quarterly earnings results on Tuesday, May 13th. The company reported ($0.26) earnings per share for the quarter, beating analysts' consensus estimates of ($0.35) by $0.09. The company had revenue of $0.01 million for the quarter, compared to analysts' expectations of $0.00 million. Altimmune had a negative return on equity of 65.44% and a negative net margin of 451,200.00%. During the same period last year, the firm earned ($0.34) earnings per share. As a group, research analysts forecast that Altimmune will post -1.35 earnings per share for the current year.

Institutional Trading of Altimmune

A number of large investors have recently made changes to their positions in ALT. GAMMA Investing LLC lifted its stake in Altimmune by 214.2% in the first quarter. GAMMA Investing LLC now owns 6,745 shares of the company's stock valued at $34,000 after buying an additional 4,598 shares during the last quarter. SBI Securities Co. Ltd. acquired a new position in shares of Altimmune in the 4th quarter valued at $45,000. Magnus Financial Group LLC acquired a new position in shares of Altimmune in the 1st quarter valued at $50,000. Headland Capital LLC purchased a new stake in Altimmune in the 1st quarter valued at $50,000. Finally, Geneos Wealth Management Inc. acquired a new stake in Altimmune during the 1st quarter worth $50,000. 78.05% of the stock is owned by institutional investors and hedge funds.

Altimmune Company Profile

Altimmune, Inc, a clinical stage biopharmaceutical company, focuses on developing treatments for obesity and liver diseases. The company's lead product candidate, pemvidutide, a GLP-1/glucagon dual receptor agonist that is in Phase 2 trial for the treatment of obesity and metabolic dysfunction-associated steatohepatitis.